Maria C Carrillo
Overview
Explore the profile of Maria C Carrillo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
189
Citations
28964
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khachaturian Z, Carrillo M, Khachaturian A
Alzheimers Dement
. 2025 Feb;
21(2):e14534.
PMID: 40009569
In the last two decades, the Alzheimer's Disease Neuroimaging Initiative (ADNI) has significantly advanced our understanding, technologies, and methods for detecting and diagnosing Alzheimer's disease and related dementias. This perspective...
2.
Katsumi Y, Touroutoglou A, Brickhouse M, Eloyan A, Eckbo R, Zaitsev A, et al.
Alzheimers Dement
. 2025 Feb;
21(2):e14489.
PMID: 39968692
Introduction: Early-onset and late-onset Alzheimer's disease (EOAD and LOAD, respectively) have distinct clinical manifestations, with prior work based on small samples suggesting unique patterns of neurodegeneration. The current study performed...
3.
Hammers D, Musema J, Eloyan A, Thangarajah M, Taurone A, La Joie R, et al.
J Prev Alzheimers Dis
. 2025 Feb;
:100075.
PMID: 39956674
Background: As literature suggests that Early-Onset Alzheimer's Disease (EOAD) and late-onset AD may differ in important ways, need exists for randomized clinical trials for treatments tailored to EOAD. Accurately measuring...
4.
Putcha D, Katsumi Y, Touroutoglou A, Eloyan A, Taurone A, Thangarajah M, et al.
Alzheimers Res Ther
. 2025 Feb;
17(1):38.
PMID: 39915859
Background: The clinical presentations of early-onset Alzheimer's disease (EOAD) and late-onset Alzheimer's disease are distinct, with EOAD having a more aggressive disease course with greater heterogeneity. Recent publications from the...
5.
Ashton N, Keshavan A, Brum W, Andreasson U, Arslan B, Droescher M, et al.
Alzheimers Dement
. 2025 Feb;
21(2):e14508.
PMID: 39907496
Introduction: The Alzheimer's Association Global Biomarker Standardization Consortium conducted a blinded case-control study to learn which phosphorylated tau (p-tau) assays provide the largest fold-changes in Alzheimer's disease (AD) versus non-AD...
6.
Rabinovici G, Knopman D, Arbizu J, Benzinger T, Donohoe K, Hansson O, et al.
J Nucl Med
. 2025 Jan;
PMID: 39778970
The Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging convened a multidisciplinary workgroup to update appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to...
7.
Rabinovici G, Knopman D, Arbizu J, Benzinger T, Donohoe K, Hansson O, et al.
Alzheimers Dement
. 2025 Jan;
21(1):e14338.
PMID: 39776249
Introduction: The Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging convened a multidisciplinary workgroup to update appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and...
8.
Weninger S, Irizarry M, Fleisher A, Leon T, Maruff P, Miller D, et al.
Alzheimers Dement (N Y)
. 2025 Jan;
10(4):e70015.
PMID: 39748838
Highlights: The Alzheimer's Association Research Roundtable (AARR) convened leaders from industry and academia, as well as patients, clinicians, and government and regulatory agency scientists to discuss the topic, "Alzheimer's Disease...
9.
Jack C, Graf A, Burnham S, Doty E, Moebius H, Montenigro P, et al.
Alzheimers Dement (N Y)
. 2025 Jan;
10(4):e70013.
PMID: 39748835
Highlights: The Alzheimer's Association Research Roundtable (AARR) convened leaders from industry, academia, and government, to review the , and gather industry perspectives and feedback on these revised criteria before its...
10.
Hammers D, Eloyan A, Taurone A, Thangarajah M, Gao S, Beckett L, et al.
Alzheimers Dement
. 2024 Dec;
21(2):e14439.
PMID: 39713873
Introduction: Early-onset Alzheimer's disease (EOAD) manifests prior to the age of 65, and affects 4%-8% of patients with Alzheimer's disease (AD). The current analyses sought to examine longitudinal cognitive trajectories...